Positive results for Shionogi's COVID-19 therapeutic S-217622

7 February 2022

Japanese drug major Shionogi (TYO: 4507) has completed its analysis of the Phase IIa part of a Phase II/III clinical trial of S-217622, an orally administered antiviral drug for COVID-19, and presented the results today, sending the firm’s shares up 3% to 7,984 yen.

During the presentation, in addition to results from secondary analyses of the antiviral effect, which is the primary endpoint of the Phase IIa part of the Phase II/III clinical trial, symptom improvement, exacerbation prevention, and safety results were newly disclosed.

According to CNA News, Japanese Prime Minister Fumio Kishida said on Monday the government would consider granting conditional early approval for Shionogi’s oral COVID-19 treatment. Mr Kishida told a televised parliamentary committee meeting that provided the drug's safety and efficacy are confirmed by clinical trials "we would like to review it promptly."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK